Evidence map›Paper›PMID 25848338›Full record

ArticleCurrent oncology (Toronto, Ont.)2015

A Canadian national expert consensus on neoadjuvant therapy for breast cancer: linking practice to evidence and beyond.

C E Simmons, S Hogeveen, R Leonard, Y Rajmohan, D Han, A Wong, J Lee, M Brackstone, J F Boileau, R Dinniwell and 1 more

Abstract read
In one paragraph

Article in Current oncology (Toronto, Ont.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

C E SimmonsDivision of Medical Oncology, BC Cancer Agency, Vancouver, BC.
S HogeveenDivision of Medical Oncology, St. Michael's Hospital, Toronto, ON.
R LeonardDivision of Medical Oncology, BC Cancer Agency, Vancouver, BC.
Y RajmohanDivision of Medical Oncology, BC Cancer Agency, Vancouver, BC.
D HanDivision of Medical Oncology, St. Michael's Hospital, Toronto, ON.
A WongDivision of Medical Oncology, St. Michael's Hospital, Toronto, ON.
J LeeDivision of Radiation Oncology, Sunnybrook Odette Cancer Centre, Toronto, ON.
M BrackstoneDivision of Surgical Oncology, London Health Sciences Centre, London, ON.
J F BoileauDivision of Surgical Oncology, Jewish General Hospital, Montreal, QC.
R DinniwellDivision of Medical Oncology, St. Michael's Hospital, Toronto, ON.
S GandhiDivision of Medical Oncology, Sunnybrook Odette Cancer Centre, Toronto, ON.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUse of the neoadjuvant approach to treat breast cancer patients has increased since the early 2000s, but the overall pathway of care for such patients can be highly variable. The aim of our project was to establish a multidisciplinary consensus among clinicians with expertise in neoadjuvant therapy (nat) for breast cancer and to determine if that consensus reflects published methods used in randomized controlled trials (rcts) in this area.

methodsA modified Delphi protocol, which used iterative surveys administered to 85 experts across Canada, was established to obtain expert consensus concerning all aspects of the care pathway for patients undergoing nat for breast cancer. All rcts published between January 1, 1967, and December 1, 2012, were systematically reviewed. Data extracted from the rcts were analyzed to determine if the methods used matched the expert consensus for specific areas of nat management. A scoring system determined the strength of the agreement between the literature and the expert consensus.

resultsConsensus was achieved for all areas of the pathway of care for patients undergoing nat for breast cancer, with the exception of the role of magnetic resonance imaging in the pre-treatment or preoperative setting. The levels of agreement between the consensus statements and the published rcts varied, primarily because specific aspects of the pathway of care were not well described in the reviewed literature.

conclusionsA true consensus of expert opinion concerning the pathway of care appropriate for patients receiving nat for breast cancer has been achieved. A review of the literature illuminated gaps in the evidence about some elements of nat management. Where evidence is available, agreement with expert opinion is strong overall. Our study is unique in its approach to establishing consensus among medical experts in this field and has established a pathway of care that can be applied in practice for patients receiving nat.

Indexed as

Breast cancerconsensuslocally advanced breast cancerneoadjuvant chemotherapyneoadjuvant endocrine therapypathway of care

Identifiers

PMID25848338
PMCPMC4381790

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.